Pfizer Inc
Analysis Terminal
Aggregated from brotherhood trade streams
"Pfizer's stock edged higher following its second-quarter report, where the company surpassed Wall Street's revenue and profit expectations for Q2 CY2026. This performance occurred despite a substantial decrease in COVID-19 pill revenue. Additionally, Pfizer boosted its 2026 sales outlook, contributing to the positive market reaction."
Asset Intelligence
Pfizer Hikes 2026 Sales Outlook By $500 Million On Second-Quarter Beat
Pfizer stock inched higher early Tuesday on a solid second-quarter report that included a sales guidance boost.
NYSE Content Update: ADI to Make NYSE Trading Debut After Spin-Off
The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.
Pfizer Covid Pill Revenue Plunges 95%. Why Earnings Are Lifting the Stock Anyway.
Pfizer beats earnings forecasts for the second quarter, while BioNTech’s results miss expectations due to weak Covid vaccine demand.
Pfizer’s (NYSE:PFE) Q2 CY2026: Beats On Revenue
Global pharmaceutical company Pfizer (NYSE:PFE) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 2.6% year on year to $15.03 billion. The company expects the full year’s revenue to be around $61.5 billion, close to analysts’ estimates. Its non-GAAP profit of $0.77 per share was 12.9% above analysts’ consensus estimates.
Pfizer (NYSE:PFE) Beats Q2 Expectations and Raises 2026 Revenue Guidance
Pfizer beats Q2 estimates, raises 2026 revenue guidance midpoint, but full-year outlook still below consensus. Stock edges higher premarket.
Coherent, Palantir, SpaceX, Caterpillar, Pfizer, and More Stocks That Explain Today’s Market
Palantir and Coherent stocks are rising sharply. SpaceX will issue its first earnings report after the closing bell Tuesday.
Pfizer’s Quarterly Results Beat Expectations on Cancer, Heart Drugs
Rising sales of drugs for cancer and heart disease helped offset steep declines for Pfizer’s Covid-19 products.
Pfizer (PFE) Reports Positive Phase 3 LITFULO Data In Vitiligo
Pfizer (NYSE:PFE) reported positive Phase 3 results for LITFULO in nonsegmental vitiligo. The company plans to pursue global regulatory filings for LITFULO as an oral therapy for this autoimmune skin disease. For investors watching Pfizer, this update highlights an area of its late stage pipeline that sits outside its COVID and oncology businesses. Nonsegmental vitiligo is a chronic condition with limited systemic treatment options, so additional clinical data around efficacy and safety is...
Pfizer Q2 earnings on deck: What to expect
Pfizer faces $17 billion patent cliff as investors brace for earnings
Pfizer (PFE) Q2 Earnings and Revenues Top Estimates
Pfizer (PFE) delivered earnings and revenue surprises of +13.24% and +4.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Stocks Rise Pre-Bell Ahead of Latest Round of Earnings; Investors Gauge Uncertainty Over Potential US-Iran Deal
US equity futures were tracking in the green on Tuesday as traders await the latest batch of corpora
AstraZeneca-Bristol Myers: The Floodgates for Biotech Mergers Are Open
Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.
Pfizer Q2 2026 earnings beat, revenue guidance raised
The drugmaker posted adjusted earnings of 77 cents per share and now expects full-year revenue of $60.5 billion to $62.5 billion
Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings
Pfizer beats earnings forecasts for the second quarter, while BioNTech’s results miss expectations due to weak Covid vaccine demand.
Stock Market Today: Futures Jump After Dow Closes at Record; Palantir, Caterpillar Shares Soar; Oil Falls Further on US-Iran Deal Optimism
Stock futures pointed to a strong opening Tuesday, a day after the Dow Jones Industrial Average set a new closing record, as Palantir led tech shares higher and oil prices fell further.
Integrity Notice
TWB Intelligence is provided for mastery education only. Market data is sourced via institutional nodes and may contain inaccuracies. Trade with discipline.